Epilepsy Clinical Trial Pipeline Analysis: Emerging Therapies from 20+ Companies Driving the Future of Seizure Management | DelveInsight

DelveInsight's Epilepsy Pipeline Insight 2026 provides comprehensive insights into the evolving therapeutic landscape for epilepsy, a chronic neurological disorder characterized by recurrent seizures resulting from abnormal electrical activity in the brain. The report offers an in-depth assessment of disease overview, pipeline therapeutics, clinical development activities, therapeutic assessment, unmet needs, market dynamics, and the pharmaceutical companies developing innovative treatment approaches to improve seizure control and patient outcomes.

Key Takeaways from the Epilepsy Clinical Trial Landscape Report

DelveInsight's Epilepsy pipeline report highlights an active research landscape with 20+ companies developing novel therapies across multiple stages of clinical development.
Key Epilepsy companies include Xenon Pharmaceuticals, Stoke Therapeutics, Jazz Pharmaceuticals, Trevena, Cassava Sciences, Autifony Therapeutics, QurAlis Corporation, NeuroPro Therapeutics, UCB Biopharma, and others.
Promising Epilepsy pipeline therapies include XEN1101, STK-001, AUT-00201, SAN2355, TRV-045, Simufilam, NPT-2042, QRL-101, Alprazolam, and others.

Request a sample and discover the latest advances in the Epilepsy pipeline:
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Epilepsy?

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal or excessive electrical discharges within the brain. It is considered a spectrum disorder because seizure types, underlying causes, and disease severity vary widely among patients. Potential causes include prenatal or perinatal brain injury, traumatic brain injury, brain tumors, genetic abnormalities, metabolic disturbances such as altered blood glucose or sodium levels, and infections, although the underlying cause remains unknown in many patients. Common symptoms include convulsions, altered consciousness, cognitive impairment, sensory disturbances, behavioral changes, sudden collapse, and loss of awareness. Globally, epilepsy affects approximately 50 million people, with an annual incidence of around 50 per 100,000 individuals and a prevalence of 5-10 per 1,000 population. Diagnosis typically relies on electroencephalography (EEG) and magnetic resonance imaging (MRI), while treatment primarily consists of antiepileptic drugs (AEDs), dietary interventions, and epilepsy surgery for selected patients.
Emerging Epilepsy Drug Profiles

XEN1101: Xenon Pharmaceuticals
XEN1101 is a novel, orally administered Kv7.2/Kv7.3 potassium channel opener being developed by Xenon Pharmaceuticals for the treatment of epilepsy. By enhancing potassium channel activity, the therapy reduces neuronal excitability and lowers seizure frequency. Clinical studies have demonstrated dose-dependent seizure reduction with a favorable safety profile, supporting its advancement into Phase III clinical development.

STK-001: Stoke Therapeutics
STK-001 is an investigational antisense oligonucleotide therapy being developed by Stoke Therapeutics. Administered through intrathecal injection, the therapy utilizes Targeted Augmentation of Nuclear Gene Output (TANGO) technology and is currently in Phase III development for epilepsy, representing an innovative precision medicine approach targeting the underlying genetic mechanisms of disease.

Learn more about the novel and emerging Epilepsy pipeline therapies:
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Epilepsy Clinical Trial Landscape

• In December 2025, Xenon Pharmaceuticals announced new interim 48-month data from its ongoing X-TOLE open-label extension study evaluating XEN1101 (azetukalner) in patients with focal onset seizures, along with additional real-world evidence and preclinical epilepsy data.
• In April 2023, Xenon Pharmaceuticals initiated a multicenter, long-term Phase III clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of XEN1101 in adults with focal onset seizures and primary generalized tonic-clonic seizures.
• In January 2026, Rapport Therapeutics announced plans to initiate a Phase III program for RAP-219 in focal onset seizures while expanding its epilepsy portfolio into primary generalized tonic-clonic seizures.
• In December 2025, Neurona Therapeutics presented updated clinical data from its ongoing Phase I/II studies evaluating NRTX-1001, a one-time allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy.
• In August 2025, Jazz Pharmaceuticals entered into a global licensing agreement with Saniona to obtain exclusive worldwide rights for SAN2355, a subtype-selective Kv7.2/Kv7.3 activator being developed for epilepsy and related neurological disorders.

Scope of the Epilepsy Pipeline Report

• Coverage: Global
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy
• Therapeutic Assessment by Clinical Stages: Preclinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutic Assessment by Route of Administration: Oral, Intravenous, Intrathecal Injection, Parenteral
• Therapeutic Assessment by Molecule Type: Small Molecules, Antisense Oligonucleotides
• Key Epilepsy Companies: Xenon Pharmaceuticals, Stoke Therapeutics, Jazz Pharmaceuticals, Trevena, Cassava Sciences, Autifony Therapeutics, QurAlis Corporation, NeuroPro Therapeutics, UCB Biopharma, and others.
• Key Epilepsy Pipeline Therapies: XEN1101, STK-001, AUT-00201, SAN2355, TRV-045, Simufilam, NPT-2042, QRL-101, Alprazolam, and others.

Dive deep into comprehensive insights on emerging Epilepsy therapies:
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Epilepsy Pipeline Report Introduction
• Executive Summary
• Disease Overview
• Signs and Symptoms
• Causes
• Diagnosis and Treatment
• Pipeline Therapeutics
• Late-Stage Products (Phase III)
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I/II)
• Early-Stage Products (Phase I)
• Preclinical Products
• Therapeutic Assessment
• Inactive Products
• Collaborations, Licensing and Funding Analysis
• Key Companies
• Key Pipeline Products
• Unmet Needs
• Market Drivers and Barriers
• Future Perspectives
• Appendix

For further information on the Epilepsy pipeline therapeutics, visit:
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.